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A B S T R A C T
Timataxel (13-(N-Boc-3-i-butylisoserinoyl-4,10-β-diacetoxy-2-α-benzoyloxy-5-β-20-epoxy-
1,13-α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene), used to be called TM-2, is a novel
semi-synthetic promising candidate for cancer treatment. However the preformulation study
showed that TM-2 was insoluble and chemically instable in water, which would limit its
application.This study aimed at the preparation of Timataxel lipid microspheres (TM-2 LMs)
and investigated the difference between TM-2 LMs and TM-2 solution in pharmacokinet-
ics. In this work, the final formulation was as follows: 0.10% (w/v) TM-2; 10.00% (w/v) oil
phase (long chain triglyceride:media chain triglyceride = 2.50%:7.50%); 1.40% (w/v) phos-
pholipid; 0.02% (w/v) NaH2PO4; 2.25% (w/v) glycerin and water to a total volume of 100 ml.
The particle size distribution, content and entrapment efficacy were 205.0 ± 43.3 nm, 101.00%,
and 99.12%, respectively. TM-2 LMs were stable during storage at 25 °C for 3 months, even
under the condition of 60 °C and 4500 lx for 10 d. Phosphatidylethanolamine (PE) in phos-
pholipid may contribute to the stability of TM-2 LMs. The pharmacokinetic parameters for
TM-2 LMs were as follows: AUC(0-∞) 3663.71 μg/l h and the clearance 2.26 l/h/kg. As for so-
lution, these parameters were 1712.52 μg/l h and 4.77 l/h/kg, respectively. The t1/2 of TM-2
LMs was similar to TM-2 solution. The pharmacokinetic results indicated that the AUC of
TM-2 LMs was larger, the clearance was smaller than that of TM-2 solution. In a word, lipid
microspheres were a promising drug delivery system for TM-2.
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Paclitaxel, which was first extracted from the stem bark of Taxus
brevifolia, exhibited excellent anti-tumor effect. The antitu-
mor mechanism of paclitaxel is to combine with β-tubulin
subunit, inhibit microtubule depolymerization, and finally lead
to apoptosis [1,2]. Considering its superiority in the treat-
ment of cancer, taxanes had attracted interests all over the
world. Currently, taxane derivatives like paclitaxel, docetaxel
and cabazitaxel have been commercialized as intravenous in-
jections for years [3]. Multidrug resistance, mainly caused by
overexpression of P-glycoprotein (P-gp), has limited the appli-
cation of docetaxel and paclitaxel [4]. P-gp acts as an energy
dependent drug efflux pump which could transport drugs to
the extracellular medium [5], and meanwhile, paclitaxel and
docetaxel are substrates of P-gp.Thus, it is essential to modify
the structure of taxanes to improve activity especially against
multidrug resistant tumor.
Timataxel (TM-2, C43H57NO14), one of the novel semi-synthetic
taxanes, has lower affinity to P-gp than docetaxel, and its struc-
ture was listed in Fig. 1. In vitro study has revealed that TM-2
exhibits more promising efficacy on a variety of human tumor
lines than docetaxel or larotaxel, especially on multidrug re-
sistant cancer cell lines involving KB/VCR and MCF-7/ADR [6,7].
The inhibition rate of A549 human lung xenografts was up to
82.24% [6,8]. Based on these encouraging results,TM-2 was se-
lected for further preclinical study.
For many drugs, insufficient solubility and less stability in
water limit their clinical use. Usually, the commercial taxane
formulations are made up of Cremophor EL or Polysorbate 80,
ethanol and water. Cremophor EL and Polysorbate 80 are non-
ionic surfactants that are responsible for the occurrence of side
effects, including acute hypersensitivity reactions and periph-
eral neurotoxicity [3]. What’s more, these solvents were
supposed to be bound with alterations in the pharmacoki-
netic characteristics after i.v. administration [9]. So a suitable
carrier is required to reduce these adverse reactions.
Lipid microspheres (LMs) mainly consist of oil, phospho-
lipid and water. Usually, drugs are incorporated in oil which
is also formed in the internal phase.This kind of structure could
protect drugs from hydrolysis, reduce irritation and other side
effects, and sustain drug release [10,11]. LMs are biocompatible,
biodegradable, and simply applied for large-scale manufac-
ture [12]. In addition, tumor is different from normal tissue that
could increase drug retention due to enhanced permeation and
retention effect [13]. Besides, tumors need higher energy which
could be supplied by LMs [14].Thus, the encapsulation of TM-2
into LMs could increase drug accumulation in tumor and
improve therapeutic efficacy.What’s more, our previous study
had shown that TM-2 was insoluble in water but lipophilic, so
LMs seem to be an attractive carrier for it [6].
The stable pH for TM-2 is 5.5–6.0, and TM-2 is liable hydro-
lysis in excessive acid media and alkaline media [6]. So pH is
a key factor during the preparation of TM-2 LMs.While in our
previous study, when TM-2 LMs were prepared, the final pH
varied within a wide range, which made the quality of the final
product uncontrollable.Moreover, the oil phase of previousTM-2
LMs was media chain triglyceride (MCT) only; there was some
disadvantage compared with mixed oil. In this paper, a new
formulation containing MCT and long chain triglyceride (LCT)
for Timataxel lipid microspheres (TM-2 LMs) was prepared.The
pH was well controlled by NaH2PO4 and phospholipid, and the
effect of different phospholipid on the stability of TM-2 LMs
was studied.The stability ofTM-2 LMswas investigated in detail,
including autoclaving stability, freezing and thawing stabil-
ity, dilution stability and acceleration stability. Finally, the
pharmacokinetic characteristics ofTM-2 LMs were investigated.
2. Materials and methods
2.1. Materials, reagents, and animals
Timataxel (TM-2, purity >99%) was kindly supplied by School
of Pharmacy, Fudan University (Shanghai, China). Cabazitaxel
(CBZ, purity >98%) was synthesized in the Medicinal Chemis-
try Lab of Yantai University (Yantai, China). Long chain
triglyceride (LCT) and media chain triglyceride (MCT) were pur-
chased fromTieLing Beiya Pharmaceutical Co. (Tieling, China).
Egg lecithin PL-100M was provided by Shanghai Advanced
Vehicle Technology Pharmaceutical Co., Ltd. (China). Lipid E80
and Lipid S100 were purchased from Lipid KG (Ludwigshafen,
Germany). Glycerol was purchased from Zhe-Jiang Suichang
Glycerol Plant (Zhejiang, China). All other chemicals and re-
agents were of HPLC or analytical grade.
Male Sprague-Dawley (SD) rats, weighing 200 ± 10 g, were
kindly provided by the Experimental Animal Center of Shenyang
Pharmaceutical University (Shenyang, China).The animal study
was conformed to the Guideline for Animal Experimentation
of Shenyang Pharmaceutical University.
2.2. Preparation of TM-2 LMs
TM-2 LMs were prepared by high-pressure homogenization
method. Considering the drug loading (1 mg/ml), 10% (w/v) oil
phase was selected for further study according to our previousFig. 1 – Chemical structure of Timataxel.
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study [6]. The specific steps were as follows: firstly, the phos-
pholipid was dispersed in the mixture of MCT and LCT at 70 °C
in a constant temperature water bath, then when the phos-
pholipid dissolved, TM-2 was added At the same time, the
aqueous phase was prepared by combining a mixture of glyc-
erol and NaH2PO4, heated to 75 °C. After that, to gain a coarse
emulsion, the water phase was slowly added into the oil phase
with high speed sheer mixing at 10,000 r/min for 3 min. Then
the volume was adjusted to 100 ml and the pH was adjusted
to 5.0 with 0.1 mol/l phosphate solution. Subsequently, the
coarse emulsion was passed through a high pressure homog-
enizer (AH 100D; ATS Engineering, Inc., China) to obtain the
final emulsion. At last, TM-2 LMs were sealed in vials under
nitrogen gas and sterilized at 121 °C for 8 min.
2.3. Characterization of TM-2 LMs
The particle size distribution (PSD) was measured by NicompTM
380 Particle Sizing system (Zeta Potential/Particle Sizer
NICOMPTM 380ZLS, Santa Barbara, California, USA), which was
also used to determine the zeta-potential of the LMs. A digital
pH-meter type PB-10 (Sartorius, Germany) was used to measure
the pH of TM-2 LMs.
The drug content was determined by high-performance
liquid chromatography (HPLC) method.The HPLC system con-
sisted of a Chromaster-5110 pump, a Chromaster-5210
autosampler, a Chromaster-5310 column oven and a
Chromaster-5410 UV detector (Hitachi Company, Japan). The
mobile phase consisted of acetonitrile-water (60:40, v/v) with
a flow rate of 1.2 ml/min, and the wavelength of the UV and
the column temperature were 227 nm and 35 °C, respec-
tively. The samples were prepared as follows: 1 ml TM-2 LMs
were transferred into a 25 ml volumetric flask and diluted with
ethanol, then the volumetric flask was shaken and the resul-
tant solution was used for HPLC analysis after passing through
0.22 μm microporous membranes (Jinlong®, Tianjin Keyilong
Experimental Equipment Co., Ltd.).
The entrapment efficiency (EE) of TM-2 LMs was mea-
sured by ultracentrifugation method to determine the
concentration of TM-2 in water phase [15]. Briefly, about 4 ml
TM-2 LMs was transferred into a polyallomer tube. After ul-
tracentrifugation 2 h at 40,000 r/min, the bottom aqueous phase
was collected with a syringe needle. 1 ml of the acquired
aqueous phase was diluted to 10 ml with ethanol, and the re-









In the equation, Ctotal refers to the content of drug in TM-2
LMs, Cwater refers to the content of TM-2 in aqueous phase.
2.4. Stability assessment
2.4.1. Autoclaving
TM-2 LMs were prepared according to Section 2.2. After being
sealed in vials, TM-2 LMs samples were autoclaved at 121 °C
for 8, 10, and 15 min, respectively. Finally, the drug content, pH
and particle size were determined to evaluate the stability of
TM-2 LMs according to Section 2.3.
2.4.2. Freezing and thawing test
TM-2 LMs were prepared according to Section 2.2. Then the
samples were stored at −20 °C for 12 h following thawing at
room temperature for 12 h. After that, the physical appear-
ance and PSD were determined according to Section 2.3. The
freezing and thawing test would last for three cycles.
2.4.3. Stability against dilution
Four groups of TM-2 LMs samples were prepared according to
Section 2.2 to study the dilution stability. The first two group
samples were diluted fivefold with 5% glucose, and then stored
at room temperature and 4 °C, respectively.The other two group
samples were diluted with 0.9% saline following the steps above.
The particle size was determined at intervals of 0, 1, 2, 4, 6, 8,
10, 12 and 24 h according to Section 2.3.
2.4.4. Acceleration stability test
Acceleration stability test consisted of two parts: stress test and
storage test. The stress test was carried on under the condi-
tion of 60 °C or 4500 lx. TM-2 LMs prepared as in Section 2.2
were divided into two parts and stored at 60 °C or 4500 lx for
10 d, respectively.The samples were selected every 5 d to evalu-
ate PSD, ζ-potential, pH value, EE and drug content.
One new batch of TM-2 LMs was prepared to investigate the
storage stability at 25 °C for 3 months. Parameters similar to
the stress test were monitored at the time intervals of 0, 1, 2
and 3 months.
2.5. Evaluation of TM-2 LMs in vivo
A pharmacokinetic study was carried out to evaluate the char-
acteristic of TM-2 LMs (1 mg/ml) in vivo as compared withTM-2
aqueous injection (1 mg/ml). TM-2 LMs were prepared as in
Section 2.2. As for TM-2 solution, 60 mg TM-2 was formulated
in polysorbate 80 (1.56 g) then diluted with 13% ethanol (w/
w), and 5% dextrose solution was added to get the final solution.
The animals were randomly divided into two groups with
six animals in each group. Then, TM-2 LMs were adminis-
trated to the first group via the caudal vein at a dose of 8 mg/
kg, andTM-2 solution was given to the latter group at the same
dose level.After dosing, blood samples were collected into hepa-
rinized tubes at 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h,
then centrifuged immediately at 4000 r/min for 10 min.The har-
vested plasma samples were stored at −20 °C until analysis.
The method of sample preparation was reported previ-
ously [16]. In short, 100 μl plasma samples were spiked with
10 μl IS (CBZ, 1000 ng/ml methanol solution) working solu-
tion.And then themixture was extracted with 2 ml methyl tert-
butyl ether by vortexing for 10 min. 1.8 ml supernatant was
collected after centrifugation at 13,000 r/min for 10 min and
evaporated to dryness at 35 °C under a stream of nitrogen.The
residue was redissolved in 100 μl of the mixture of acetonitrile/
water (60/40, v/v) followed by centrifugation for 10 min at
13,000 r/min. Finally, 5 μl acquired supernatant was injected.
The content of TM-2 in plasma was determined on an
ACQUITYTM UPLC system (Waters Corp., Milford, MA, USA) and
aWaters XevoTQ triple quadrupole mass spectrometer (Waters
Corp., MA, USA) equipped with an electrospray ionization
source. The analysis time was 3 min. The mobile phase was
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composed of acetonitrile (A) and water (B, containing 5 mM am-
monium acetate). During the first 1 min, solution A increased
from 60 to 95% and held for 1.3 min. Then solution A de-
creased to the initial rate and kept there until 3.0 min. The
capillary voltage was 3.0 kV; the cone voltage was 35 V forTM-2
and 33 V for CBZ.The collision energy was 25 eV and 22 eV for
TM-2 and CBZ, respectively.
The pharmacokinetic parameters of TM-2 were analyzed by
DAS 2.1 software supplied by the Pharmacological Society of
China (Beijing, China). SPSS 19.0 (Statistical Package for the
Social Science) was used to analyze and compare the phar-
macokinetic parameters betweenTM-2 LMs andTM-2 solution
by an independent samples t-test.
3. Results and discussion
3.1. Preparation of TM-2 LMs
Lipid microspheres have been particularly attractive as a part
of parenteral nutrition therapy for decades. However, there are
some adverse effects associated with LCT limiting its appli-
cation, including the increasing of pulmonary artery pressure,
suppressing gastrointestinal function, and so on [17,18]. MCT
is rapidly cleared, carnitine-independent transport and even-
tually transfer to ketone bodies [17,19]. Neuro-toxicity and
Candida albicans connected with MCT could not be ignored
[17,20]. When an emulsion containing a mixture of LCT and
MCT was infused, there was no effect on reticuloendothelial
function [18]. Also the emulsion containing MCT and LCT was
recommended for patients with acute respiratory distress syn-
drome and acute pancreatitis [21].Thus the emulsion of mixed
oil could reduce the risk associated with pure MCT or LCT based
lipid emulsions.As time goes by, drug has the tendency to sepa-
rate out of emulsion. So an adequate solubility for drug in oil
is necessary. Our previous study showed that TM-2 had a much
higher solubility in MCT (>100 mg/ml) than in LCT (25.36 mg/
ml) [6]. Thus, a large amount of MCT may prevent drug from
precipitating. Taken the safety and stability into consider-
ation, a mixture of MCT and LCT (7.5:2.5, w/w) was chosen as
the oil phase.
Considering that TM-2 was preferred to an acid environ-
ment [6], 2 mM/l NaH2PO4 was chosen. Four representative
formulations with different phospholipids were prepared to
develop optimum TM-2 LMs. The results that were listed in
Table 1 indicated that the particle size of formulation with dif-
ferent phospholipid changedmarkedly during the manufacture
of TM-2 LMs except PL-100M. To investigate this phenom-
enon, the compound of phospholipid was compared.The major
composition of different phospholipid was shown in Table 2.
Compared with E80 and S100, the content of PE and choles-
terol in PL-100M was much higher. Considering that cholesterol
could regulate the phase state of the membrane [22], it was
suspected that cholesterol led to the stable state. So the par-
ticle size of TM-2 LMs containing E80 was compared with that
of TM-2 LMs containing E80 and cholesterol. The results were
listed in Fig. 2. It could be concluded that regardless of the pres-
ence of cholesterol, the particle size changed markedly after
sterilization.Thus, cholesterol was not the decisive factor.The
head groups of phosphatidylcholine (PC) and phosphatidyle-
thanolamine (PE) were different, the latter was smaller [23].
Phospholipids were arranged on the surface of lipidmicrosphere
droplets, the larger head group of PC made it need more space
than chains, while the space for the head group of PE was the
same with chains. So the existence of PE would make the phos-
pholipid layer close and in order, and heating would bring out
less change to it. This could be proved by comparing the for-
mulation of S100 with E80. There was almost no PE in S100,
and the coarse emulsion was creaming after 2 min, while E80
was stable. So PE may be the key factor leading to the stabil-
ity of TM-2 LMs. After 2 months, there were visible oil droplets
when the amount of PL-100M was 1.2%. Hence, 1.4% PL-100M
was chosen to prepare TM-2 LMs.
The stable pH forTM-2 is 5.5–6.0, while the pH of LMs would
decrease during storage due to the hydrolysis of phospho-
lipid and the release of free fatty acid. So the final pH of TM-2
LMs, which is about 6.0, is better. The effect of phospholipid
on pH was different during the preparation of LMs. The pH of
LMs containing E80 or S100 decreased slightly. This might be
because during the preparation of TM-2 LMs, considerable heat
input led to the hydrolysis of phospholipid, while the pH of
LMs containing PL-100M increased. The difference of pH may
be connected with the characteristic of PL-100M. PL-100M is
made from a suspension whose pH is 6.5–9.5 containing two
different kinds of phospholipid, which is different from E80 or




It is known to us that shorter sterilization with higher tem-
perature is better for the stability of drug than longer
sterilization with lower temperature. Thus, 121 °C steam ster-
ilization was employed.The results were presented in Table 3.
LMs are thermodynamically and dynamically unstable, so harsh
autoclaving condition would bring out adverse effects on the
stability of TM-2 LMs. The content and pH of TM-2 LMs
Table 1 – The effect of phospholipid on particle size of
TM-2 LMs before/after sterilization (mean ± SD; n = 3).
Phospholipid Particle size (nm)
Before sterilization After sterilization
E80 1.2% 248.4 ± 75.3 498.0 ± 231.4
S100 1.2% ND ND
PL-100M 1.2% 244.6 ± 50.9 246.2 ± 76.3
PL-100M 1.4% 235.1 ± 66.8 239.8 ± 26.1
Table 2 – The content of PC, PE and Cholesterol in
different commercial natural-extracted phospholipid.
Phospholipid PC (%) PE (%) Cholesterol (%)
PL-100M 78 18 <5.0
E80 82 9.2 <1.0
S100 96 <0.1 ND
The data of PC and PE contents are quoted from inspection report
of bought commercial lecithin.
774 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 7 7 1 – 7 7 9
decreased as time went by. The decrease of pH may connect
with the hydrolysis of phospholipid and the oil phase.The deg-
radation of phospholipid followed Arrhenius kinetics [25], high
temperature sterilization led to the release of free fatty acid
which finally resulted in the decrease of the pH of TM-2 LMs.
The hydrolysis of phospholipid may cause the leakage of drug
which was susceptible to hydrolysis in water, so the drug
content decreased.
3.2.2. Freezing and thawing test
The freeze-thawing test is a method to evaluate the stability
of LMs. As shown in Fig. 3, the particle size was slightly larger
after 3 cycles.This was different from previous study that freez-
ing resulted in a much larger droplet size due to the
condensation of lipid droplets [26]. This may be partially due
to the existence of LCT. Oil could penetrate into the surface
membrane, which would change the mean spontaneous cur-
vature of membrane that plays an important role in the stability
of emulsion [26]. With the existence of LCT, less MCT would
penetrate into the surface of emulsion, then the spontane-
ous curvature of membrane would have a less decrease. In
addition, it was reported that during the freeze-thawing cycles,
salt combined with glycerin may suppress ice crystal forma-
tion and maintain the density of droplets similar to that in
solution [27]; as a result, the droplet coalescence would be
suppressed.
3.2.3. Stability against dilution
Lipid microspheres are occasionally demanded to be diluted,
frequently with saline (0.9%) or glucose (5%) solution.The result
of particle size that was shown in Fig. 4A and B revealed that
0.9% NaCl resulted in a larger particle size at room tempera-
ture, while the other three groups almost remained unchanged.
The similar result has been shown in a previous study [28], and
it revealed that this phenomenon was related to the reduced
electrostatic repulsion.The result illustrated that once diluted,
the lipid microspheres should be injected as soon as pos-
sible, although the change was within permitted limit.
3.2.4. Acceleration stability test
The influence of heat and light on the degradation of TM-2 LMs
was investigated under the circumstance of 60 °C and 4500 lx,
respectively, and the result was given in Table 4. The pH dra-
matically decreased, especially at 60 °C, while other parameters
almost kept unchanged.This may be because the elevated tem-
perature accelerated the degradation of phospholipid, and thus
resulted in the formation of free fatty acids. The result indi-
cated that TM-2 LMs were relatively stable. However, to
Fig. 2 – The effect of E80 or E80 with cholesterol on the particle size of TM-2 LMs in the process of sterilization (mean ± SD;
n = 3).
Table 3 – The characterization of pH, particle size and content of TM-2 LMs under different autoclaving time (mean ± SD;
n = 3).













8 6.07 ± 0.05 218.0 ± 61.7 98.71 ± 0.18
10 6.07 ± 0.04 6.06 ± 0.06 220.0 ± 61.0 225.9 ± 65.7 98.75 ± 0.17 96.26 ± 0.16
15 6.03 ± 0.58 217.4 ± 68.0 92.37 ± 0.11
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minimize the degradation of drug, it was suggested that TM-2
LMs should be stored avoiding high temperature and light.
The results of TM-2 LMs stored at 25 ± 2 °C were shown in
Table 5. During 3 months, the change ofTM-2 LMs was in quali-
fied range over the study period, indicating thatTM-2 LMs were
a stable intravenous administration system.
3.3. Pharmacokinetic study
A pharmacokinetic study was designed to compare the dif-
ference between TM-2 LMs and TM-2 solution. The curves of
the mean plasma concentration–time were shown in Fig. 5, and
the corresponding pharmacokinetic parameters were listed in
Table 6. From Fig. 5, the concentration of TM-2 in plasma de-
creased rapidly regardless of TM-2 LMs or TM-2 solution. The
AUC(0-∞) of TM-2 LMs was 3663.71 μg/l h with 1712.52 μg/l h for
TM-2 solution. The clearance for TM-2 LMs and TM-2 solu-
tion was 2.26 l/h/kg and 4.77 l/h/kg, respectively. However, the
half-lives (t1/2) of the two carriers were similar. All in all, the
TM-2 LMs group had higher AUC(0-t) and AUC(0-∞), smaller clear-
ance (CL) and lower apparent volume of distribution (P < 0.05).
The analytical data suggested that TM-2 in both drug carriers
followed a triphasic model which was consistent with previ-
ous findings [16].
Compared with theTM-2 solution group, theTM-2 LMs group
had a much higher AUC, which stated in previous study that
Fig. 3 – The characterization of particle size of TM-2 LMs after three freeze-thawing cycles (mean ± SD; n = 3).
Table 4 – The characterization of TM-2 LMs under the condition of high temperature and high light for 10 d (mean ± SD;
n = 3).
High temperature test (60 °C)
Time (d) Content (%) EE (%) pH ζ-potential (mV) PSD (nm)
0 101.00 ± 0.85 99.12 ± 0.01 6.16 ± 0.05 −41.03 ± 1.97 205.0 ± 43.2
5 99.95 ± 1.54 99.34 ± 0.01 5.16 ± 0.55 −46.26 ± 1.03 205.1 ± 61.5
10 95.28 ± 1.28 98.13 ± 0.00 5.08 ± 0.03 −46.33 ± 1.50 208.5 ± 52.1
High-light exposure test (4500 lx)
0 101.00 ± 0.85 99.12 ± 0.01 6.16 ± 0.05 −41.03 ± 1.97 205.0 ± 43.2
5 100.80 ± 1.53 99.30 ± 0.00 6.11 ± 0.05 −46.35 ± 1.44 206.9 ± 62.7
10 100.84 ± 1.70 99.13 ± 0.02 5.95 ± 0.02 −49.58 ± 1.67 210.2 ± 42.3
Table 5 – The characterization of TM-2 LMs stored at 25 ± 2 °C for 3 months (mean ± SD; n = 3).
Time (month) Content (%) pH ζ-potential (mV) Particle size (nm)
0 98.90 ± 0.00 5.78 ± 0.06 −43.54 ± 1.14 230.9 ± 47.6
1 97.73 ± 0.01 5.37 ± 0.09 −44.43 ± 1.02 232.5 ± 47.9
2 96.47 ± 0.08 5.37 ± 0.09 −54.32 ± 3.37 228.7 ± 68.9
3 96.56 ± 0.01 5.10 ± 0.09 −42.70 ± 1.77 244.1 ± 30.3
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when lipophilic drugs were given in lipid microspheres, it dem-
onstrated higher plasma concentrations following i.v.
administration than in solution [29]. What made the differ-
ence between themwas probably the drug carrier.TM-2 solution
was prepared by dissolving drug in polysorbate 80 which was
quickly eliminated after i.v. administration [3], thus it may result
in a precipitation of TM-2 with different particle size. Particle
size of droplets had an effect on drug distribution.The smaller
one (0.2–0.7 μm) may be trapped into liver, spleen, and lung,
while the larger one (>7 μm) would be taken in the capillary
bed of the lung [30]. So TM-2 solution would distribute wider
in vivo thanTM-2 LMs and then contribute to a decrease in AUC.
Fig. 4 – (A) The influence of saline (0.9%) on the particle size of TM-2 LMs at the temperature of 4 °C and room temperature
after diluted fivefold (mean ± SD; n = 3). (B) The influence of glucose (5%) on the particle size of TM-2 LMs at the temperature
of 4 °C and room temperature after diluted fivefold (mean ± SD; n = 3).
Table 6 – The main pharmacokinetic parameters in rats
of TM-2 after intravenous administration of TM-2 LMs
and TM-2 solution at a dose of 8 mg/kg (mean ± SD;
n = 6).
Parameters TM-2 LMs TM-2 solution
AUC(0-t) (μg/l h) 3405.89 ± 611.13 1433.32 ± 174.69
AUC(0-∞) (μg/l h) 3663.71 ± 762.62 1712.52 ± 217.20
t1/2 (h) 13.76 ± 7.58 14.22 ± 7.28
CL (l/h/kg) 2.26 ± 0.44 4.77 ± 0.76
V (l/kg) 42.58 ± 18.86 93.67 ± 39.28
Cmax (μg/l) 6450.00 ± 1948.51 1563.62 ± 207.02
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In addition, the release of TM-2 seemed to be a solubility-
limited process.TM-2 was lipophilic and located in the internal
phase of LMs which was stable in a certain period of time. So
drug was released slowly from LMs to the blood. And when the
release of drug reached a saturated state, the release was
stopped, following a dynamic balance. As a result,TM-2 loaded
in LMs penetrated into the tissue slowly than in solution and
contributed to a higher AUC.
The larger clearance ofTM-2 solutionmay be associated with
polysorbate 80. The quick elimination of polysorbate 80 may
lead to the increase of unbound drug (not bound to polysor-
bate 80 and to plasma protein) which caused a faster clearance
in patient [31]. Similar to Taxotere®, TM-2 solution was made
by adding polysorbate 80. So it was suspected that polysor-
bate 80 would increase the clearance of TM-2, and the similar
result was got in the comparison of Larotaxel solution and lipid
microsphere [30].
4. Conclusions
A TM-2 LM was successfully prepared, then the final formula
was composed of TM-2 0.10%, oil phase 10.00%
(MCT:LCT = 7.5:2.5), PL-100M 1.40%, NaH2PO4 0.024%, glycerol
2.25%, and water to a total volume of 100 ml. PE may contrib-
ute to the stability of TM-2 LMs.The stability of TM-2 LMs was
investigated thoroughly. The optimum sterilization condition
for TM-2 LMs was 121 °C for 8 min. Freezing and thawing test
indicated that TM-2 LMs could undergo dramatic tempera-
ture fluctuations. If dilution is necessary, glucose (5%) seemed
to be a better choice than saline. Stress test for 10 d sug-
gested that high temperature and light should be avoided during
the storage of TM-2 LMs. And storage test indicated that TM-2
LMs were stable for at least 3 months. The pharmacokinetic
study revealed that TM-2 LMs could increase the AUC and de-
crease the clearance and apparent volume of distribution. So
LMs could be a suitable drug delivery for TM-2.
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